2025 Controlled & Modified Drug Release Summit

For today’s drug manufacturer, the idea of collaboration is one that should never leave the table. Successful organizations will ensure that their internal departments are working hand-in-hand with one another. And, even more successful companies know that there could be huge benefits to reap by collaborating with others across the healthcare ecosystem. To instill this idea of collaborating for success, we are going to play a fun little ice-breaker game.

As chronic diseases become more prevalent in an aging global population, the need for controlled- and extended-release formulations is growing. These dosage forms offer an appealing way to minimize pill burden for patients and improve adherence to medications. While many extended-release formulations rely on cellulosic polymers, such as HPMC, combinations of excipients may offer key technical and patient benefits to a formulation, such as smaller tablet size and better control over drug release. In this presentation, we will explore the potential of Lubrizol’s Carbopol® polymers to enhance extended-release performance and overcome shortcomings of single-polymer solutions. Join us to learn more about:

• The current formulation and manufacturing landscape for extended-release tablets
• Key technical and patient-centric challenges in extended-release
• Benefits of Carbopol® polymers for matrix tablets, including precedence of use
• Case studies demonstrating robust extended-release performance from Carbopol-HPMC matrices
• Strategies for enhanced formulations via granulation and direct compression

Innovations in drug discovery and repurposing have generated renewed interest in small molecule development. While these efforts have grown the global project pipeline, many candidates suffer from solubility and bioavailability challenges. In order to formulate these complex molecules, new technologies and formulation approaches are needed to meet technical requirements while ensuring patient safety/compliance. Lubrizol Life Science’s injectable-grade Apisolex™ and oral-grade Apinovex™ polymers were designed to overcome poor solubility and unlock the future of small molecule drug delivery. Join us to learn about:

• Key considerations for novel solubility enhancement technologies
• New tools for solubility enhancement: Apinovex™ and Apisolex™ polymer technologies
• Case study data demonstrating solubility enhancement and high stable drug loading
• Safety/toxicity updates and future plans
• The importance of manufacturing and quality support for novel technologies